Weighing risks and benefits of liraglutide--the... [N Engl J Med. 2010] - PubMed

Liraglutide and calcitonin. [J Diabetes. 2010]
Liraglutide and calcitonin.
Bloomgarden Z. J Diabetes. 2010 Dec; 2(4):223-4.
Liraglutide. [Nat Rev Drug Discov. 2010]
Liraglutide.
Drucker DJ, Dritselis A, Kirkpatrick P. Nat Rev Drug Discov. 2010 Apr; 9(4):267-8.
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. [Contemp Clin Trials. 2011]
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Viereck C, Boudes P. Contemp Clin Trials. 2011 May; 32(3):324-32. Epub 2011 Jan 23.
Review A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. [Clin Ther. 2009]
Review A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E, Sesti G. Clin Ther. 2009 Nov; 31(11):2472-88.
Review [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2]. [Med Monatsschr Pharm. 2009]
Review [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
Jahn E, Sausele T. Med Monatsschr Pharm. 2009 Nov; 32(11):402-7.

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications. [Diabetes Ther. 2011]
Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications.
Unger JR, Parkin CG. Diabetes Ther. 2011 Mar; 2(1):29-39. Epub 2011 Jan 18.
Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus. [Indian J Endocrinol Metab. 2011]
Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus.
Dharmalingam M, Sriram U, Baruah MP. Indian J Endocrinol Metab. 2011 Jan; 15(1):9-17.
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. [Diabetes Metab Syndr Obes. 2010]
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes.
Neumiller JJ, Sonnett TE, Wood LD, Setter SM, Campbell RK. Diabetes Metab Syndr Obes. 2010 Jul 14; 3:215-26. Epub 2010 Jul 14.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabet...
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
N Engl J Med. 2010 Mar 4 ;362(9):774-7. Epub 2010 Feb 17 .

PubMed
Estimates of excess deaths associated with body mass index and other anthropomet...
Estimates of excess deaths associated with body mass index and other anthropometric variables.
Am J Clin Nutr. 2009 Apr ;89(4):1213-9. Epub 2009 Feb 3 .

PubMed
Current diagnostic techniques in genital herpes: their role in controlling the e...
Current diagnostic techniques in genital herpes: their role in controlling the epidemic.
Clin Lab. 2000 ;46(11-12):591-607.

PubMed
Health care use and health and functional impact of developmental disabilities a...
Health care use and health and functional impact of developmental disabilities among US children, 1997-2005.
Arch Pediatr Adolesc Med. 2009 Jan ;163(1):19-26.

PubMed
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue in...
CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.
Nat Med. 2009 Aug ;15(8):914-20. Epub 2009 Jul 26 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed